[Featured Stock] Nexten Bio Rises on News of Collaboration with Global No.1 Diabetes Treatment Company

[Asia Economy Reporter Jang Hyowon] NexTurn Bioscience is showing strength following news that Rosbivo, a U.S. new drug development company acquired by NexTurn Bioscience, is pursuing collaboration with the world's No. 1 diabetes treatment company.

As of 2:11 PM on the 9th, NexTurn Bioscience is trading at 18,500 KRW, up 1.65% from the previous day.

According to industry sources on the day, Rosbivo completed the first conference call meeting in mid-May regarding research on the diabetes drug 'RSVI-301' with Novo Nordisk, the global No. 1 diabetes treatment company.

Founded in 1923 by Danish physician August Krogh, a Nobel Prize laureate in Physiology or Medicine, Novo Nordisk is a pharmaceutical company. It recorded sales of 23 trillion KRW last year and is listed on stock exchanges including New York, London, and Copenhagen. Its market capitalization on the New York Stock Exchange is approximately 159 trillion KRW.

Meanwhile, NexTurn Bioscience acquired a 50% stake in Rosbivo last May. Rosbivo has filed four U.S. and international patents related to RSVI-301/302 through the University of Nevada.